Table 3 Univariate analysis for overall survival

Location of primary tumor (rectum vs colon)

0.531 (0.212–1.333)

0.178

Age (≥65 vs <65)

7.492 (2.941–9.084)

<0.001

Sex (female vs male)

2.038 (0.908–4.578)

0.085

Neoadjuvant chemotherapy (Yes vs No)

1.114 (0.460–2.698)

0.811

Tumor grade (moderate/poor vs well)

1.332 (0.312–5.693)

0.698

T stage (T4 vs T1-3)

4.324 (1.857–10.068)

0.001

N stage (N2 vs N0,1)

1.906 (0.854–4.251)

0.115

Resection site

 Liver

1

 Lung

0.311 (0.041–2.335)

0.256

 Others (ovary, uterus, bladder)

1.036 (0.345–3.108)

0.950

Use of Cetuximab at 1st post-operative chemotherapy (Yes vs No)

3.777 (0.850–16.779)

0.081

Use of Bevacizumab at 1st post-operative chemotherapy (Yes vs No)

0.899 (0.267–3.027)

0.863

KRAS (mutation vs mutation)

0.500(0.198–1.267)

0.144

KRAS

 Wild

1

 12th

0.330 (0.076–1.428)

0.138

 13th

0.675 (0.227–2.010)

0.481